Therapeutic Area
Rare Disease CDMOs
Compare CDMOs with rare disease manufacturing expertise for orphan drugs, enzyme replacement therapies, gene therapies, and ultra-small batch production. Filter by modality, scale, and regulatory experience.
88 companies listed
About Rare Disease Drug Manufacturing
Rare disease (orphan drug) manufacturing presents unique challenges. Patient populations are small -- often under 10,000 patients worldwide -- so batch sizes are correspondingly small. But the manufacturing complexity is often extreme: gene therapies, enzyme replacement therapies, substrate reduction therapies, and RNA therapeutics dominate the pipeline. The cost per dose can exceed $100,000, making manufacturing efficiency and batch success rates critically important.
Gene therapy is reshaping rare disease treatment. Over 30 approved gene therapies target rare diseases, with hundreds more in clinical development. Manufacturing AAV vectors for conditions like spinal muscular atrophy, hemophilia, and inherited retinal dystrophy requires specialized viral vector production facilities, scalable purification processes, and potency assays specific to each product. CDMOs with flexible, multi-product vector manufacturing capabilities are in high demand.
Flexibility beats scale for rare disease CDMOs. Unlike cardiovascular or diabetes drugs that need massive throughput, rare disease products need CDMOs that can efficiently handle 10-100 batch campaigns per year. Multi-product facilities with short changeover times, validated cleaning procedures for potent and biologic products, and regulatory experience with orphan drug designations (FDA, EMA) provide the most value to sponsors in this space.
Companies (88)
GP Pharm S.A.
Spain
GP Pharm S.A. is a Spanish CDMO specializing in sterile injectable manufacturing, with particular expertise in long-acting injectable depot formulations including microspheres and sustained-release systems. The company offers contract development and manufacturing services from formulation development through commercial production, with capabilities in aseptic processing, fill/finish for vials and pre-filled syringes, and lyophilization.
Small Molecule Drug ProductFormulation DevelopmentBiologics Drug Product
Grand River Aseptic Manufacturing (GRAM)
United States
Grand River Aseptic Manufacturing (GRAM) is a premier US-based CDMO specializing exclusively in sterile injectable fill-and-finish services for liquid and lyophilized vials, pre-filled syringes, and cartridges. The company serves pharmaceutical and biotech clients with capabilities spanning clinical through commercial-scale production for biologics, small molecules, and vaccines. GRAM also partners with drug delivery device innovators to offer solutions for autoinjectors and on-body delivery systems.
Frequently Asked Questions
What makes rare disease manufacturing different from other therapeutic areas?+
Three factors distinguish rare disease manufacturing. First, batch sizes are small (often 100-10,000 doses per year), so CDMO economics must work at low volumes. Second, products are often highly complex -- gene therapies, enzyme replacements, and other biologics that require sophisticated manufacturing and analytics. Third, the regulatory pathway offers incentives (orphan drug designation, accelerated approval) but also unique challenges around clinical endpoints and post-market commitments.
How do orphan drug economics affect CDMO selection?+
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
